Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24106466 | 0.85 | ALDH1A1 (0.49) | MMEACECPA1ACE2PPARG | |
| SCHEMBL24930325 | 0.83 | SIGMAR1 (0.52) | — | |
| SCHEMBL597195 | 0.83 | SIGMAR1 (0.52) | — | |
| SCHEMBL11439744 | 0.81 | LTA4H (0.48) | LTA4HSLC2A1PPARGPPARAPPARD | |
| SCHEMBL11446097 | 0.81 | LTA4H (0.48) | LTA4HSLC2A1PPARGPPARAPPARD | |
| SCHEMBL11434236 | 0.81 | LTA4H (0.58) | LTA4HSLC2A1MMEACECPA1 | |
| SCHEMBL10720375 | 0.80 | SIGMAR1 (0.46) | MMEACECPA1ACE2 | |
| SCHEMBL20172543 | 0.80 | SLC6A4 (0.58) | LTA4HSMN1; SMN2 | |
| SCHEMBL13166015 | 0.80 | SLC6A4 (0.58) | LTA4HSMN1; SMN2 | |
| SCHEMBL13166017 | 0.80 | SLC6A4 (0.58) | LTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | LTA4H 4731/4885SLC2A1 3661/4885MME 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.